On March 28th, Genfleet Therapeutics publicly announced a patent for an oral KRAS G12D inhibitor, with the patent number WO2024061370A1.

U.S. Sanctions ENHERTU®, a Pioneer HER2-Targeting Drug, for Metastatic Solid Cancers with HER2 Positivity After Initial Treatments.

Bitopic ligands of GPCRs (G protein-coupled receptors) refer to a single chemical entity composed of two pharmacophoric groups covalently linked together.

FDA Clears Abecma from Bristol Myers and 2seventy bio for Treatment of Relapsed or Stubborn Multiple Myeloma Following Two Previous Therapies.

On March 28th, the journal "Cell" published an online research paper titled "Flexible Scaffold-based Cheminformatics Approach for Polypharmacological Drug Design".

Immunome, Inc. plans to reveal early data on IM-3050, their lead drug featuring lutetium-177, targeting the fibroblast activation protein.

X4 Pharmaceuticals announced preliminary results from its Phase 2 trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without injected G-CSF in patients with idiopathic, cyclic, or congenital neutropenia.

Werewolf Therapeutics Reveals Early Stage Study Outcomes Highlighting the Cancer-Fighting Capabilities of Immune-Stimulating Drugs WTX-518 and WTX-712.

Deucrictibant is a new, potent oral small-molecule bradykinin B2 receptor antagonist, originally developed by the Pharvaris team.

Edgewood Oncology reveals encouraging outcomes from a research-driven trial for BTX-A51 in early tests on liposarcoma models.

An immunosuppressant is a type of medication that suppresses or reduces the strength of the immune system.

Alnylam Unveils Encouraging Outcomes from Phase 2 KARDIA-2 Trial with Zilebesiran on Top of Usual Hypertension Medications in Subjects with Poorly Managed High Blood Pressure.